Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotine + prazosin is a combination of two small molecule drugs, each with distinct mechanisms of action. Nicotine is a stimulant that acts as an agonist at various neuronal nicotinic acetylcholine receptors, leading to increased dopamine release and stimulation of the central and peripheral nervous systems. Prazosin is an alpha-1 adrenergic receptor antagonist that causes vasodilation by blocking the vasoconstrictive effects of catecholamines on blood vessels, primarily used for hypertension. The combination has been studied in preclinical models for its effects on nicotine withdrawal symptoms and may have potential utility in smoking cessation or modulating cardiorespiratory responses to nicotine[3][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotine + prazosin.